News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
U.S. equities were higher at midday as concerns oil prices would spike because of the U.S. attack on Iran diminished.
First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...
Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...
MarketBeat on MSN3h
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.
Zacks Investment Research on MSN4d
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback